Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Multienzyme complexes or mixtures of enzymes

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424940100 - ENZYME OR COENZYME CONTAINING

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424940210 Pancreatin 8
Entries
DocumentTitleDate
20110177050COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising 07-21-2011
20080279839Composition With a Fungal (Yeast) Lipase and Method For Treating Lipid Malabsorption in Cystic Fibrous as Well as People Suffering From Pancreatic Lipase Insufficiency - The invention provides compositions and methods for treating pancreatic enzyme insufficiency, such as the pancreatic enzyme insufficiency associated with cystic fibrosis. The invention also provides compositions comprising lipase from 11-13-2008
20110195059Enzymatic Prevention and Control of Biofilm - The invention provides methods, compositions, and kits for removal of biofilms from surfaces. The methods described herein comprise simultaneous or sequential application of a perhydrolase enzyme and a mixture of other enzymes, such as proteases, glucanases, esterases, mannanases, phospholipases, cellulases, and/or amylases, to a biofilm on a surface, to effect removal of the biofilm.08-11-2011
20100158885METHOD AND MATERIAL FOR SITE ACTIVATED COMPLEXING OF BIOLOGIC MOLECULES - Methods of and compositions for producing and using plant-based materials are provided. The methods include using biopolymers or their synthetic equivalents combined with a stable source of reactive oxygen species that when applied to or combined with a separate source of oxido-reducing enzyme or catalyst will cause the formation of an activated biopolymer with increased protein binding affinity and microbial control activities.06-24-2010
20130034530Dietary Supplement Cognitive Support System - The present invention relates to a nutritional supplement composition, comprising a therapeutically effective amounts of Vitamin C, Vitamin D3, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic acid, Vitamin B12, Pantothenic acid, Calcium, Magnesium, Zinc, Chromium, Sugar, Protein, Acetyl-L-Carnitine, Dimethylaminoethanol complex, Phosphatidylserine complex, L-Glutamine, N-Acetyl-L-Tyrosine, L-Phenylalanine, Taurine, Methionine, Valine, Isoleucine, 5 Hydroxytryptophan, L-Taurine, N-Acetyl-Tyrosine, N-Acetyl-L-Cysteine, Alpha Lipoic Acid, Alpha Glycerylphosphoricholine complex, Bacopa Monnieri extract, Gingko Biloba extract, Passion flower, Lemon Balm, Gotu Kola, Ashwagandha, Choline Bitartrate complex, Panax Ginseng extract, Turmeric, Organic freeze dried fruit juice blends (concord grape, red raspberry, pineapple, cranberry, acai, pomegranate, acerola cherry, bilberry, lingonberry, black currant, aronia, sour cherry, black raspberry), Organic freeze dried greens blends (barley grass, broccoli, beet, carrot, alfalfa, oat), and Protein digestive enzyme blends (Protease 4.5, peptidase, bromelain, protease 6.0, protease 3.0, L planatrum, B bifidum) in a mixture to provide optimal cognitive function.02-07-2013
20130034532NANOZYMES, METHODS OF MAKING NANOZYMES, AND METHODS OF USING NANOZYMES - Embodiments of the present disclosure provides for nanozymes, methods of making nanozymes, methods of using nanozymes, and the like.02-07-2013
20130034529NATURAL COMPOSITIONS AND METHODS OF PROMOTING WOUND HEALING - Compositions comprising honey, myrhh, and 02-07-2013
20100111920METHODS AND COMPOSITIONS FOR THE TREATMENT OF VAGINAL DISEASES EMPLOYING PEROXIDE-PRODUCING ENZYMES AND PEROXIDASES - A therapeutic composition for vaginal administration based on the generation of a biocidal anion by an enzymatic reaction catalyzed by a peroxidase. The peroxide utilized by the peroxidase enzyme can be endogenous or can be generated by the action of an oxidase enzyme on a suitable substrate. Therapeutic compositions according to the present invention are useful for the treatment of vaginal diseases and conditions, including bacterial and fungal infections.05-06-2010
20130034531USE OF PROTEASES FOR GLUTEN INTOLERANCE - The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also be used as a prophylactic to reduce exposure to gluten oligopeptides.02-07-2013
20090317371Method, Composition, and Device, for the Treatment of Amylase Malfunctions / Inactivity in Association with Saccharides (Mainly Polysaccharides) Based Diseases - Physiological protein and enzyme complex having active Trimethylglycine, active amylases, active lipases, and active proteases, of human (saliva enzymes), yeast, plant, fungi, and or microbial origin, preferably digestive enzyme complex such as, Trimethylglycine, 4-α-D-glucan glucanohydrolase; Exo-1,4-α-glucosidase; Beta-fructofuranosidase; Protease (3.0); Pectinase; Lipase; Cellulase; Lactase; Malt Diastase, or digestive enzyme complex containing proteins and enzymes for the treatment of high levels of saccharides and correction of amylases malfunctioning activity or inactivity in the body. The invention also relates to the production of pharmaceutical compositions suitable for such treatment. A preferred variant of the invention relates to use of this enzyme complex having Trimethylglycine, amylolytic, lipolytic, and proteolytic activity, especially salivary, gastric, pancreatic and intestinal enzyme complex for the treatment of malfunctioning, or absent amylases enzymes activity but not deficiency, in association with or without excess saccharides in the body.12-24-2009
20110002906Purification and Isolation of Recombinant Oxalate Degrading Enzymes and Spray-Dried Particles Containing Oxalate Degrading Enzymes - The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.01-06-2011
20090092591Use of a Mixture of Superoxide Dismutase and Catalase for Treating Inflammatory Skin Lesions - The invention concerns the use of a mixture of superoxide dismutase and catalase for preparing a topical composition for treating inflammatory skin lesions, said lesions being selected among the group consisting of dermal fibroses, epidermal keratoses, cheloid scars or hypertrophic eschars. The inventive compositions are formulated to obtain all galenic forms conventionally used for applying a topical composition on the skin such as for example milk, cream, lotion, plaster or patch, as powder sticks to be solubilized in water or physiological serum prior to use.04-09-2009
20130058910DECONTAMINATION OF CHEMICAL AND BIOLOGICAL AGENTS - A system includes at least one oxidase. at least one haloperoxidase; at least a first polymer including groups exhibiting nucleophilic activity for organophosphorus compounds, and a source of halide ions to serve as a substrate for haloperoxidase-catalyzed generation of halogens. The source of halide ions may, for example, include salt crystals or a salt in an extended release system. In a number of embodiments, the first polymer includes halide ions.03-07-2013
20080219964Methods and products for enhancing energy and nutrition in human beings - Methods for increasing energy in men and women include ingesting internally, twice a day, products that include, for women, multivitamins, multiminerals, high-calcium bone support products, high-ORAC super food products, and enzymes, and, for men, multivitamins, multiminerals, prostate support products, high-ORAC super food products, and enzymes.09-11-2008
20090047266Lipases for Pharmaceutical Use - The pharmaceutical use of lipases related to a variant of the 02-19-2009
20090010910COMPOSITIONS AND METHODS FOR DERMATOLOGICAL WOUND HEALING - The invention relates to compositions for debriding damaged skin comprising at least one enzymatic debriding agent and at least one antiseptic compound comprising heavy metal ions. The present invention further relates to kit and methods for topical debridement of damaged skin, particularly of burned skin.01-08-2009
20110280853COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF STAPHYLOCOCCUS AUREUS ON SURFACES - Compositions and methods for treating or preventing 11-17-2011
20110280854COMPOSITIONS AND METHODS FOR THE TREATMENT OR THE PREVENTION OF E. COLI INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF E. COLI SURFACES - Compositions and methods for treating or preventing 11-17-2011
20090053188METHOD OF PREVENTING REDUCED FEED INTAKE IN ANIMALS AND TREATMENT OF DISEASE CONDITIONS - The present invention relates to a method for substantially preventing a reduction in feed intake in an animal which occurs when said animal is administered an antibiotic, the method comprising administering to an animal in need of prevention of a reduction in feed intake, increasing doses of a composition comprising one or more antibiotics. The present invention also relates to a method for treating laminitis and fermentative acidosis in an animal in need of said treatment, the method comprising administering increasing doses of a composition comprising one or more antibiotics. The present invention further relates to a method for treating equine grass sickness and pulpy kidney in an animal in need of said treatment, the method comprising administering increasing doses of a composition comprising one or more antibiotics.02-26-2009
20080317726Proteases for Pharmaceutical Use - The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from 12-25-2008
20100124548Pharmaceutical product - The present invention relates to methods and products for the treatment of any disorder or condition, which is associated with abnormal amount of non-collagenous protein, or abnormal oligomerization or dysfunction of non-collagenous protein, such as adiponectin in the blood circulation and/or tissue of a patient. The treatment comprises that functional form of the non-collagenous protein is adjusted in the blood circulation and/or tissue of the patient substantially to the level it is in the blood circulation and/or tissue of a healthy person, by using lysyl hydroxylase and/or glycosyl-transferase activities of LH3 or other lysyl hydroxylase to modify the non-collagenous protein to HMW or other functional form.05-20-2010
20120107296FEED SUPPLEMENT - The present invention relates to a feed supplement comprising a phytase and a lipolytic enzyme, wherein said lipolytic enzyme has lipase activity at a pH in the range of about pH1.5 to about pH3.5.05-03-2012
20110200575METALLO-LACTOFERRIN-COENZYME COMPOSITIONS TO IMPROVE SLEEP PATTERNS - Formulations are provided for the improvement of sleep patterns. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as 5-hydroxy-L-tryptophan (5-HTP), choline, melatonin, milk protein hydrolysate, L-arginine, and L-carnitine. The compositions can be administered orally in a variety of forms.08-18-2011
20110171189COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising 07-14-2011
20110200574USE OF PROTEASES FOR GLUTEN INTOLERANCE - The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also be used as a prophylactic to reduce exposure to gluten oligopeptides.08-18-2011
20090053187Agent exhibiting bactericidal action with respect to vegetative and spore cells bacillus anthrasis, anthrax preventing and treating method - The invention relates to the field of biotechnology, medicine, and veterinary and can be used for anthrax prevention and treatment. The proposed drug has a bactericidal effect on vegetative and spore cells of 02-26-2009
20100143320DIETARY SUPPLEMENT - The invention relates to a dietary supplement that promotes proper ingestion and proper digestion of animal and/or vegetable proteins. The supplement comprises an enzyme mixture containing amylase, lactase and bromelain in the following dosage by weight: 15 mg to 90 mg amylase, 18 mg to 90 mg lactase and 6 mg to 80 mg bromelain.06-10-2010
20120070423ORAL COMPOSITION AND METHOD OF FORMING AND USING SAME - An oral composition for the treatment of dry mouth symptoms and other conditions, a method of forming the oral composition, and a method of using the oral composition are disclosed. The oral composition includes a plurality of enzymes to prevent formation of and/or facilitate the break up of biofilm in an oral cavity and a metal ion management system to inhibit growth of gram negative bacteria.03-22-2012
20090238811Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials - Disclosed herein are a coating, a textile finish, a wax, elastomer, a filler, an adhesive, or a sealant, as well as polymeric materials such as a plastic, a laminate, a composite, that includes an enzyme that degrades cell wall or cell membrane components (e.g., a lysozyme, lytic transgrycosylase) alone or in combination with other enzymes such as a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme, or an antimicrobial peptide. Also disclosed herein are methods of retarding or preventing microbial growth on or in a coating, paint, textile finish, wax, elastomer, adhesive, sealant, filler, or a polymeric material, where such a surface material includes an enzyme that degrades cell wall or cell membrane components (e.g., a lysozyme, lytic transgrycosylase).09-24-2009
20100303785NOVEL THERAPEUTICS BASED ON TAU/MICROTUBULE DYNAMICS - The invention is based on the discovery of a novel neuroprotective peptide. In addition, the invention rests on the discovery that the NAP peptide enhances the association of tau and the brain-specific beta tubulin subunit. In addition, NAP modifies microtubule assembly and dynamics, in part, by affecting the tyrosination of microtubule proteins. The invention provides compositions and methods for treatment and prevention of neuronal disorders, including NAP-binding and tau-binding agents, tau peptide mimetics, NAP-like and NAP-like tau peptide mimetics.12-02-2010
20110243909Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from 10-06-2011
20100135978Proteases for Pharmaceutical Use - The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from 06-03-2010
20090324572METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF WILLIAMS SYNDROME - A therapeutic composition for the treatment of the symptoms of Williams Syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of Williams Syndrome, or the likelihood of an individual to develop Williams Syndrome is disclosed.12-31-2009
20090324571USE OF BACTERIAL AMYLASES IN FEED FOR BOVINE ANIMALS - The invention relates to the use of at least one bacterial amylase in feed for ruminant animals of the subfamily Bovinae in particular for improving milk yield, apparent digestibility of the diet fed, feedstuff dry matter disappearance, weight gain, and/or Feed Conversion Ratio (FCR). Examples of bovine animals are dairy cows and beef cattle. The invention also relates to the use of such amylases in feed and feed additives such as premix, concentrates and total mixed ration (TMR). The amylase may be used in combination with cellulase for improving milk yield and/or back fat thickness. Preferred amylases are derived from 12-31-2009
20100040592LIPASE-CONTAINING COMPOSITION AND METHODS OF USE THEREOF - Disclosed are compositions including crosslinked lipase crystals that are highly resistant to proteolysis, low pH and elevated temperature.02-18-2010
20110177049COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising 07-21-2011
20110177048COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.07-21-2011
20110150855Enzyme Composition and Use Thereof - Disclosed is a means effective for the treatment or prevention of inflammatory bowel disease. Specifically disclosed is an enzyme composition for the treatment or prevention of inflammatory bowel disease, which utilizes an enzyme capable of producing an oligosaccharide in vivo.06-23-2011
20110059062USE OF HYDROLYTIC AND OXIDATIVE ENZYMES TO DISSOLVE BIOFILM IN AIRWAY PASSAGES - A composition for removal of biofilm in the airway passage is useful for the treatment of infections such as pneumonia cause by 03-10-2011
20120171187DEBRIDING COMPOSITION FROM BROMELAIN AND METHODS OF PRODUCTION THEREOF - The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.07-05-2012
20110135621INHIBITING BACTERIAL INFECTION AND BIOFILM FORMATION - The present invention relates generally to the field of treating bacterial infections. More particularly, it relates to an antimicrobial agent and methods of eliminating biofilm and planktonic cells using the antimicrobial agent.06-09-2011
20110129454COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising 06-02-2011
20120148554THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND ANTIOXIDANT ENZYMES - Administration of an exogenous pulmonary surfactant in combination with antioxidant enzymes is effective for the prevention of bronchopulmonary dysplasia (BPD) and decreases the markers of pulmonary oxidative stress.06-14-2012
20110189153Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from 08-04-2011
20120308543Lipase Variants for Pharmaceutical Use - The pharmaceutical use of lipases related to the 12-06-2012
20090110674Health supplement - A health supplement consisting of numerous ingredients from several general groups including: anti-aging, anti-oxidant, vitamins, minerals, and elemental substances including metals. The supplement is specifically formulated for maximizing synergistic interaction of the ingredients while eliminating harmful interaction among the ingredients. A holistic approach to health is followed with ingredients to aid all systems of the human body. By addressing all human body systems, the supplement acts as a precursor to anti-aging and, when body systems are detoxified and oxidation is controlled, the effect of aging may be reversed.04-30-2009
20110044966USE OF A SUBSTANCE FOR MANUFACTURING OF A MEDICAMENT FOR TREATMENT OF COMMON COLD - A method for treatment and/or prevention of common cold caused by rhinovirus, wherein a patient in need is treated with a medicament including a hydrogen peroxide producing enzyme.02-24-2011
20100322912Combination Enzyme Therapy for Gastric Digestion of Dietary Gluten in Celiac Sprue Patients - Combination enzyme products and methods of use thereof are provided. Aspergillopepsin I is combined with a protease enzyme that provides for an additive or synergistic effect in the digestion of toxic gluten oligopeptides. The enzyme products are useful in the treatment of Celiac Sprue patients, particularly for patients who continue to exhibit signs or symptoms of active disease despite following a gluten-free diet.12-23-2010
20110110910Proteases for Pharmaceutical Use - The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from 05-12-2011
20100034797Lipase Variants for Pharmaceutical Use - The pharmaceutical use of lipases related to the 02-11-2010
20110064712Dietary Supplement Compositions and Methods of Making and Using the Same - Dietary supplement compositions are disclosed. Methods of making and using dietary supplement compositions are also disclosed.03-17-2011
20120207732COMPOSITIONS AND METHODS FOR PROMOTING NEURONAL OUTGROWTH - Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.08-16-2012
20080299102Novel BACE proteins, nucleic acid molecules therefor, novel crystal structure of novel BACE proteins, and methods for making and using - Disclosed and claimed are novel BACE proteins, crystal structures thereof, nucleic acid molecules therefor, and methods for making and using and uses of the same, especially for ascertaining inhibitors of BACE; and thus, disclosed and claimed too are inhibitors of BACE and methods of making and using the same.12-04-2008
20110091436USE OF MATRIX METALLOPROTEINASE-10 (MMP-10) FOR THROMBOLYTIC TREATMENTS - The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders.04-21-2011
20100092447METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF PRION DISEASES - A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed.04-15-2010
20100209411USE OF HYDROLYTIC AND OXIDATIVE ENZYMES TO DISSOLVE BIOFILM IN EARS - A composition for removal of biofilm in the ears is useful for the treatment of ear infections such as otitis media, particularly those infections caused by 08-19-2010
20110182873COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising 07-28-2011
20110182874COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.07-28-2011
20120315261ANTIBACTERIAL AUXILIARY AGENT COMPRISING KOMBU EXTRACT AS ACTIVE INGREDIENT, ANTIBACTERIAL COMPOSITION, AND FOOD OR BEVERAGE - Disclosed are: a method for utilizing a kombu (kelp) extract as an antibacterial auxiliary agent; and a method for utilizing a combination of the antibacterial auxiliary agent, lactoperoxidase, glucose oxidase and glucose as an antibacterial composition having a potent antibacterial activity. Specifically disclosed are: an antibacterial auxiliary agent comprising a fraction having a molecular weight of 5000 or less and produced from a kombu extract as an active ingredient; an antibacterial composition comprising the antibacterial auxiliary agent, lactoperoxidase, glucose oxidase and glucose; an antibacterial composition as mentioned above, which additionally comprises xanthane gum; and a food or beverage containing the antibacterial composition.12-13-2012
20120315260Compositions and Methods to Prevent and Treat Biofilms - Compositions and methods to treat biofilms are disclosed based on the discovery of the role of the disaccharide trehalose in microbial biofilm development. In various embodiments to treat body-borne biofilms systemically and locally, the method includes administering trehalase, the enzyme which degrades trehalose, in combination with other saccharidases for an exposition time sufficient to adequately degrade the biofilm gel matrix at the site of the biofilm. The method also includes administering a combination of other enzymes such as proteolytic, fibrinolytic, and lipolytic enzymes to break down proteins and lipids present in the biofilm, and administering antimicrobials for the specific type(s) of infectious pathogen(s) underlying the biofilm. Additionally, methods are disclosed to address degradation of biofilms on medical device surfaces and biofilms present in industrial settings.12-13-2012
20120230970METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS - A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.09-13-2012
20120251516PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT - The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells.10-04-2012
20120177624ORAL DISINFECTANT, AND FOOD ADDITIVE COMPRISING THE DISINFECTANT - Disclosed is a disinfectant which is safe, has few adverse side-effects, can be ingested together with a food or beverage by adding the disinfectant to the food or beverage, shows a bactericidal effect in the oral cavity, and has no problem even when ingested on a daily basis over a long period. Also disclosed is a food additive comprising the disinfectant. Specifically, disclosed is an oral disinfectant for the disinfection of an oral bacterium, which comprises lactoperoxidase, glucose oxidase, glucose and a pH-adjusting component.07-12-2012
20090060893Methods for enlarging the diameter of a biological conduit in a human subject - The invention provides methods for treating a an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.03-05-2009
20120263699Compositions and Methods for Preservation of Fresh Produce - The present invention is concerned with compositions and methods for treatment of fresh produce to reduce the levels of bacterial and/or fungal contamination. The compositions comprise the ingredients selected from a source of chlorite ions, enzymes, grapefruit seed extract, and an agent for adjusting the pH of the composition, and a pH buffering system to maintain a stable pH. The methods of preserving produce include applying the compositions to produce, to the trees or plants that bear produce, or to the packing materials used to pack, ship and sell the produce.10-18-2012
20110123508INSTRUMENT CLEANER - A composition or concentrate for cleaning medical or dental instruments comprising in combination a protease and a biostatically effective phenoxy alcohol such as phenoxyethanol selected such that at a working solution dilution of the combination, the phenoxy alcohol is at a concentration below the MIC of the selected phenoxy alcohol against 05-26-2011
20120328589GLUCOCEREBROSIDASE MULTIMERS AND USES THEREOF - Multimeric protein structures comprising at least two glucocerebrosidase molecules being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and uses thereof in the treatment of Gaucher disease. The multimeric protein structures are characterized by longer-lasting activity as compared to native glucocerebrosidase both in serum and in lysosomes.12-27-2012
20100233146Coatings and Surface Treatments Having Active Enzymes and Peptides - Disclosed herein are a materials such as a coating, an elastomer, an adhesive, a sealant, a textile finish, a wax, and a filler for such a material, wherein the material includes an enzyme such as an esterase (e.g., a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme), an enzyme that degrades a cell wall and/or a cell membrane component (e.g., a lysozyme, a lytic transgrycosylase, a peptidase), and/or a biocidal or biostatic peptide. Also disclosed herein are methods of decontaminating a surface comprising such a material from a chemical substrate of an enzyme such as a lipid or an organophosphorus compound, as well as reducing the growth of a microorganism on or within such a material.09-16-2010
20120321605ARTIFICIAL SALIVA COMPRISING HYALULONIC ACID - Provided is artificial saliva including hyaluronic acid (HA). The artificial saliva may be used to treat xerostomia or oral candidiasis and can be effectively used to prevent or treat complications cased by reduced secretion of saliva, since the artificial saliva is in a physiological range of human saliva and shows adequate antimicrobial activities.12-20-2012
20110158972COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES - A drug product comprising a combination of highly purified collagenase I and collagenase II from 06-30-2011
20130171121MATURATION OF GASTROINTESTINAL TRACT - The present invention provides a method to induce maturation of an immature GI-tract, such as intestine, e.g. small intestine, the method comprising the steps of administering a mixture of enzymes to the immature GI-tract, said enzymes having a pancreatic activity or action, and/or pancreatic like activity or action, and analysing the maturation process of the GI-tract to monitor said maturation process. Provided herein are also uses and kits to provide for GI-tract maturation.07-04-2013
20130129697Enhanced Staphylolytic Activity of the Staphylococcus aureus Bacteriophage vB_SauS-philPLA88 Virion-Associated Peptidoglycan Hydrolase HydH5: Fusions, Deletions and Synergy with LysH5 - Virion-associated peptidoglycan hydrolases have a potential as antimicrobial agents due to their ability to lyse Gram positive bacteria on contact. Full-length HydH5, a virion-associated peptidoglycan hydrolase from the 05-23-2013
20130129698CONJUGATED BLOOD COAGULATION FACTOR VIIA - The present invention provides a biocompatible polymer conjugated to FVIIa via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIIa, and pharmaceutical compositions comprising such conjugated forms of FVIIa.05-23-2013
20130142770BOTULINUM TOXIN COMPOSITIONS AND METHODS - Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, and cholecystitis for example.06-06-2013
20130115203Enzyme and Prebiotic Combinations for Enhancing Probiotic Efficacy - This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and α-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and β-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.05-09-2013
20130095090FACTOR VIIA COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT - Disclosed are a blood coagulation factor complex in which FacVIIa, a non-peptidyl polymer and an immunoglobulin Fc region are bonded by covalent bonds, and the uses thereof. The FacVIIa complex guarantees the in vivo activity of FacVIIa and significantly enhances the serum half life of FacVIIa, so that it is useful for developing long-acting FacVIIa formulations which can improve the compliance of role behavior of patients whose blood does not coagulate.04-18-2013
20130121982ANTIDOTE TO THE BITE OF VENOMOUS SNAKES - The present invention concerns a composition comprising a low dosage of at least one venom derived from a venomous snake, characterised in that said composition is diluted in an aqueous medium according to the Sequential Kinetic Activation method. In addition, the present invention concerns the use of said composition as an antidote against the poisoning caused by the bite of a venomous snake.05-16-2013
20130129699BOTULINUM TOXIN COMPOSITIONS AND METHODS - Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a 05-23-2013
20080199448ENZYME COMPOSITION FOR IMPROVING FOOD DIGESTION - An orally administered composition for improving food absorption and digestion contains therapeutically effective dosages of digestive enzymes and L-glutamine as active ingredients. The digestive enzymes include at least one each of a lipase, a protease, and an amylase, and at least a portion of each of these enzymes is enteric coated.08-21-2008
20110243908Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from 10-06-2011
20120276075SYNERGIC ACTION OF A PROLYL PROTEASE AND TRIPEPTIDYL PROTEASES - The present invention relates to a novel enzyme composition comprising a prolyl protease and tripeptidyl proteases having unique catalytic properties. The present invention further relates to methods for producing the enzyme composition as well as a pharmaceutical composition and a food supplement containing the enzyme composition and its use in the degradation of polypeptides.11-01-2012
20120276074COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTION - The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.11-01-2012
20130149292THROMBIN-FREE BIOLOGICAL ADHESIVE AND USE THEREOF AS A MEDICAMENT - The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor Vila and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials.06-13-2013
20130189238FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.07-25-2013
20130195828Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques - Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator.08-01-2013

Patent applications in class Multienzyme complexes or mixtures of enzymes

Patent applications in all subclasses Multienzyme complexes or mixtures of enzymes